α-Lipoic acid improves abnormal behavior by mitigation of oxidative stress, inflammation, ferroptosis, and tauopathy in P301S Tau transgenic mice

Redox Biology

Volumn 14, Issue , 2018, Pages 535-548

  Zhang, Yan Hui ^a   Wang, Da Wei ^b   Xu, Shuang Feng ^a   Zhang, Shuai ^a   Fan, Yong Gang ^a   Yang, Ying Ying ^a   Guo, Shi Qi ^a   Wang, Shan ^a   Guo, Tian ^a   Wang, Zhan You ^a   Guo, Chuang ^a  

^a NORTHEASTERN UNIVERSITY   (China)

^b China Medical University   (China)

Author keywords

Alzheimer's disease; Ferroptosis; Oxidative stress; Tau; Lipoic acid

Indexed keywords

CALCIUM; CALPAIN 1; IRON; T 5625; TAU PROTEIN; THIOCTIC ACID; MAPT PROTEIN, MOUSE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; BRAIN LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FERROPTOSIS; LEARNING; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SPATIAL MEMORY; SUPPLEMENTATION; TAUOPATHY; ANIMAL; CELL DEATH; COMPLICATION; DISEASE MODEL; DRUG EFFECT; GENETICS; INFLAMMATION; LIPID PEROXIDATION; METABOLISM; PATHOLOGY; POINT MUTATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; CELL DEATH; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; LIPID PEROXIDATION; MICE, TRANSGENIC; OXIDATIVE STRESS; POINT MUTATION; TAU PROTEINS; TAUOPATHIES; THIOCTIC ACID;

EID: 85032921364     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2017.11.001     Document Type: Article

References (70)

1. Yoshiyama, Y., Higuchi, M., Zhang, B., Huang, S.M., Iwata, N., Saido, T.C., Maeda, J., Suhara, T., Trojanowski, J.Q., Lee, V.M., Synapse loss and microglial activation precede tangles in a P301S tauopathy mouse model. Neuron 53:3 (2007), 337–351, 10.1016/j.neuron.2007.01.010.
2. Lee, V.M., Goedert, M., Trojanowski, J.Q., Neurodegenerative tauopathies. Annu. Rev. Neurosci. 24 (2001), 1121–1159, 10.1146/annurev.neuro.24.1.1121.
3. DeVos, S.L., Miller, R.L., Schoch, K.M., Holmes, B.B., Kebodeaux, C.S., Wegener, A.J., Chen, G., Shen, T., Tran, H., Nichols, B., Zanardi, T.A., Kordasiewicz, H.B., Swayze, E.E., Bennett, C.F., Diamond, M.I., Miller, T.M., Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci. Transl. Med., 9(374), 2017, 10.1126/scitranslmed.aag0481.
4. Holtzman, D.M., Carrillo, M.C., Hendrix, J.A., Bain, L.J., Catafau, A.M., Gault, L.M., Goedert, M., Mandelkow, E., Mandelkow, E.M., Miller, D.S., Ostrowitzki, S., Polydoro, M., Smith, S., Wittmann, M., Hutton, M., Tau: from research to clinical development. Alzheimer's & dementia. J. Alzheimer's Assoc. 12:10 (2016), 1033–1039, 10.1016/j.jalz.2016.03.018.
5. Perez, M., Cuadros, R., Smith, M.A., Perry, G., Avila, J., Phosphorylated, but not native, tau protein assembles following reaction with the lipid peroxidation product, 4-hydroxy-2-nonenal. FEBS Lett. 486:3 (2000), 270–274.
6. Takeda, A., Smith, M.A., Avila, J., Nunomura, A., Siedlak, S.L., Zhu, X.W., Perry, G., Sayre, L.M., In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of tau induced by 4-hydroxy-2-nonenal modification. J. Neurochem. 75:3 (2000), 1234–1241, 10.1046/j.1471-4159.2000.0751234.x.
7. Lyras, L., Cairns, N.J., Jenner, A., Jenner, P., Halliwell, B., An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J. Neurochem. 68:5 (1997), 2061–2069.
8. Berg, D., Youdim, M.B., Role of iron in neurodegenerative disorders. Top. Magn. Reson. Imaging 17:1 (2006), 5–17, 10.1097/01.rmr.0000245461.90406.ad.
9. Ward, R.J., Zucca, F.A., Duyn, J.H., Crichton, R.R., Zecca, L., The role of iron in brain ageing and neurodegenerative disorders. Lancet Neurol. 13:10 (2014), 1045–1060, 10.1016/S1474-4422(14)70117-6.
10. Garcia de Ancos, J., Correas, I., Avila, J., Differences in microtubule binding and self-association abilities of bovine brain tau isoforms. J. Biol. Chem. 268:11 (1993), 7976–7982.
11. Ledesma, M.D., Avila, J., Correas, I., Isolation of a phosphorylated soluble tau fraction from Alzheimer's disease brain. Neurobiol. Aging 16:4 (1995), 515–522.
12. Yamamoto, A., Shin, R.W., Hasegawa, K., Naiki, H., Sato, H., Yoshimasu, F., Kitamoto, T., Iron (III) induces aggregation of hyperphosphorylated tau and its reduction to iron (II) reverses the aggregation: implications in the formation of neurofibrillary tangles of Alzheimer's disease. J. Neurochem. 82:5 (2002), 1137–1147.
13. Sayre, L.M., Zelasko, D.A., Harris, P.L.R., Perry, G., Salomon, R.G., Smith, M.A., 4-hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease. J. Neurochem. 68:5 (1997), 2092–2097.
14. Persson, H.L., Yu, Z., Tirosh, O., Eaton, J.W., Brunk, U.T., Prevention of oxidant-induced cell death by lysosomotropic iron chelators. Free Radic. Biol. Med. 34:10 (2003), 1295–1305.
15. Hager, K., Kenklies, M., McAfoose, J., Engel, J., Munch, G., Alpha-lipoic acid as a new treatment option for Alzheimer's disease – a 48 months follow-up analysis. J. Neural Transm. Suppl. 72 (2007), 189–193.
16. Hager, K., Marahrens, A., Kenklies, M., Riederer, P., Munch, G., Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia. Arch. Gerontol. Geriatr. 32:3 (2001), 275–282.
17. Farr, S.A., Poon, H.F., Dogrukol-Ak, D., Drake, J., Banks, W.A., Eyerman, E., Butterfield, D.A., Morley, J.E., The antioxidants alpha-lipoic acid and N-acetylcysteine reverse memory impairment and brain oxidative stress in aged SAMP8 mice. J. Neurochem. 84:5 (2003), 1173–1183.
18. Liu, J., Head, E., Gharib, A.M., Yuan, W., Ingersoll, R.T., Hagen, T.M., Cotman, C.W., Ames, B.N., Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc. Natl. Acad. Sci. USA 99:4 (2002), 2356–2361, 10.1073/pnas.261709299.
19. Quinn, J.F., Bussiere, J.R., Hammond, R.S., Montine, T.J., Henson, E., Jones, R.E., Stackman, R.W. Jr., Chronic dietary alpha-lipoic acid reduces deficits in hippocampal memory of aged Tg2576 mice. Neurobiol. Aging 28:2 (2007), 213–225, 10.1016/j.neurobiolaging.2005.12.014.
20. Sancheti, H., Akopian, G., Yin, F., Brinton, R.D., Walsh, J.P., Cadenas, E., Age-dependent modulation of synaptic plasticity and insulin mimetic effect of lipoic acid on a mouse model of Alzheimer's disease. PloS One, 8(7), 2013, e69830, 10.1371/journal.pone.0069830.
21. Sancheti, H., Kanamori, K., Patil, I., Diaz Brinton, R., Ross, B.D., Cadenas, E., Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: a 13C NMR study. J. Cereb. Blood Flow. Metab.: Off. J. Int. Soc. Cereb. Blood Flow. Metab. 34:2 (2014), 288–296, 10.1038/jcbfm.2013.196.
22. Lovell, M.A., Xie, C., Xiong, S., Markesbery, W.R., Protection against amyloid beta peptide and iron/hydrogen peroxide toxicity by alpha lipoic acid. J. Alzheimer's Dis. 5:3 (2003), 229–239.
23. Ono, K., Hirohata, M., Yamada, M., Alpha-lipoic acid exhibits anti-amyloidogenicity for beta-amyloid fibrils in vitro. Biochem. Biophys. Res. Commun. 341:4 (2006), 1046–1052, 10.1016/j.bbrc.2006.01.063.
24. Rochette, L., Ghibu, S., Richard, C., Zeller, M., Cottin, Y., Vergely, C., Direct and indirect antioxidant properties of alpha-lipoic acid and therapeutic potential. Mol. Nutr. Food Res. 57:1 (2013), 114–125, 10.1002/mnfr.201200608.
25. Maczurek, A., Hager, K., Kenklies, M., Sharman, M., Martins, R., Engel, J., Carlson, D.A., Munch, G., Lipoic acid as an anti-inflammatory and neuroprotective treatment for Alzheimer's disease. Adv. Drug Deliv. Rev. 60:13–14 (2008), 1463–1470, 10.1016/j.addr.2008.04.015.
26. Moreira, P.I., Harris, P.L., Zhu, X., Santos, M.S., Oliveira, C.R., Smith, M.A., Perry, G., Lipoic acid and N-acetyl cysteine decrease mitochondrial-related oxidative stress in Alzheimer disease patient fibroblasts. J. Alzheimer's Dis. 12:2 (2007), 195–206.
27. Guo, C., Wang, P., Zhong, M.L., Wang, T., Huang, X.S., Li, J.Y., Wang, Z.Y., Deferoxamine inhibits iron induced hippocampal tau phosphorylation in the Alzheimer transgenic mouse brain. Neurochem. Int. 62:2 (2013), 165–172, 10.1016/j.neuint.2012.12.005.
28. Xie, Y., Hou, W., Song, X., Yu, Y., Huang, J., Sun, X., Kang, R., Tang, D., Ferroptosis: process and function. Cell Death Differ. 23:3 (2016), 369–379, 10.1038/cdd.2015.158.
29. Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., Patel, D.N., Bauer, A.J., Cantley, A.M., Yang, W.S., Morrison, B. 3rd, Stockwell, B.R., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149:5 (2012), 1060–1072, 10.1016/j.cell.2012.03.042.
30. Dixon, S.J., Stockwell, B.R., The role of iron and reactive oxygen species in cell death. Nat. Chem. Biol. 10:1 (2014), 9–17, 10.1038/nchembio.1416.
31. Zhang, S., Chai, R., Yang, Y.Y., Guo, S.Q., Wang, S., Guo, T., Xu, S.F., Zhang, Y.H., Wang, Z.Y., Guo, C., Chronic diabetic states worsen Alzheimer neuropathology and cognitive deficits accompanying disruption of calcium signaling in leptin-deficient APP/PS1 mice. Oncotarget 8:27 (2017), 43617–43634, 10.18632/oncotarget.17116.
32. Noble, W., Olm, V., Takata, K., Casey, E., O.M., Meyerson, J., Gaynor, K., LaFrancois, J., Wang, L.L., Kondo, T., Davies, P., Burns, M., Nixon, V.R., Dickson, D., Matsuoka, Y., Ahlijanian, M., Lau, L.F., Duff, K., Cdk5 is a key factor in tau aggregation and tangle formation in vivo. Neuron 38:4 (2003), 555–565, 10.1016/S0896-6273(03)00259-9.
33. Rockenstein, E., Torrance, M., Adame, A., Mante, M., Bar-on, P., Rose, J.B., Crews, L., Masliah, E., Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J. Neurosci. 27:8 (2007), 1981–1991, 10.1523/JNEUROSCI.4321-06.2007.
34. Liu, F., Grundke-Iqbal, I., Iqbal, K., Gong, C.X., Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22:8 (2005), 1942–1950, 10.1111/j.1460-9568.2005.04391.x.
35. Kopeikina, K.J., Polydoro, M., Tai, H.C., Yaeger, E., Carlson, G.A., Pitstick, R., Hyman, B.T., Spires-Jones, T.L., Synaptic alterations in the rTg4510 mouse model of tauopathy. J. Comp. Neurol. 521:6 (2013), 1334–1353, 10.1002/cne.23234.
36. Ballatore, C., Lee, V.M.Y., Trojanowski, J.Q., Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat. Rev. Neurosci. 8:9 (2007), 663–672, 10.1038/nrn2194.
37. Gomez-Isla, T., Hollister, R., West, H., Mui, S., Growdon, J.H., Petersen, R.C., Parisi, J.E., Hyman, B.T., Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann. Neurol. 41:1 (1997), 17–24, 10.1002/ana.410410106.
38. Xu, H., Rosler, T.W., Carlsson, T., de Andrade, A., Bruch, J., Hollerhage, M., Oertel, W.H., Hoglinger, G.U., Memory deficits correlate with tau and spine pathology in P301S MAPT transgenic mice. Neuropathol. Appl. Neurobiol. 40:7 (2014), 833–843, 10.1111/nan.12160.
39. Santacruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., Forster, C., Yue, M., Orne, J., Janus, C., Mariash, A., Kuskowski, M., Hyman, B., Hutton, M., Ashe, K.H., Tau suppression in a neurodegenerative mouse model improves memory function. Science 309:5733 (2005), 476–481, 10.1126/science.1113694.
40. Jiang, T., Zhang, Y.D., Chen, Q., Gao, Q., Zhu, X.C., Zhou, J.S., Shi, J.Q., Lu, H., Tan, L., Yu, J.T., TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. Neuropharmacology 105 (2016), 196–206, 10.1016/j.neuropharm.2016.01.028.
41. Ahmed, Z., Cooper, J., Murray, T.K., Garn, K., McNaughton, E., Clarke, H., Parhizkar, S., Ward, M.A., Cavallini, A., Jackson, S., Bose, S., Clavaguera, F., Tolnay, M., Lavenir, I., Goedert, M., Hutton, M.L., O'Neill, M.J., A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity. Acta Neuropathol. 127:5 (2014), 667–683, 10.1007/s00401-014-1254-6.
42. Good, P.F., Perl, D.P., Bierer, L.M., Schmeidler, J., Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann. Neurol. 31:3 (1992), 286–292, 10.1002/ana.410310310.
43. Smith, M.A., Sayre, L.M., Monnier, V.M., Perry, G., Oxidative posttranslational modifications in Alzheimer disease. A possible pathogenic role in the formation of senile plaques and neurofibrillary tangles. Mol. Chem. Neuropathol. 28:1–3 (1996), 41–48, 10.1007/BF02815203.
44. Crespo, A.C., Silva, B., Marques, L., Marcelino, E., Maruta, C., Costa, S., Timoteo, A., Vilares, A., Couto, F.S., Faustino, P., Correia, A.P., Verdelho, A., Porto, G., Guerreiro, M., Herrero, A., Costa, C., de Mendonca, A., Costa, L., Martins, M., Genetic and biochemical markers in patients with Alzheimer's disease support a concerted systemic iron homeostasis dysregulation. Neurobiol. Aging 35:4 (2014), 777–785, 10.1016/j.neurobiolaging.2013.10.078.
45. Crichton, R.R., Dexter, D.T., Ward, R.J., Brain iron metabolism and its perturbation in neurological diseases. J. Neural Transm. 118:3 (2011), 301–314, 10.1007/s00702-010-0470-z.
46. Wojtala, A., Bonora, M., Malinska, D., Pinton, P., Duszynski, J., Wieckowski, M.R., Methods to monitor ROS production by fluorescence microscopy and fluorometry. Methods Enzymol. 542 (2014), 243–262, 10.1016/B978-0-12-416618-9.00013-3.
47. Xue, H., Chen, D., Zhong, Y.K., Zhou, Z.D., Fang, S.X., Li, M.Y., Guo, C., Deferoxamine ameliorates hepatosteatosis via several mechanisms in ob/ob mice. Ann. N. Y. Acad. Sci. 1375:1 (2016), 52–65, 10.1111/nyas.13174.
48. Dumont, M., Stack, C., Elipenahli, C., Jainuddin, S., Gerges, M., Starkova, N.N., Yang, L., Starkov, A.A., Beal, F., Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J. 25:11 (2011), 4063–4072, 10.1096/fj.11-186650.
49. Avila, J., The tau code. Front Aging Neurosci., 1, 2009, 10.3389/neuro.24.001.2009.
50. Hanger, D.P., Anderton, B.H., Noble, W., Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol. Med. 15:3 (2009), 112–119, 10.1016/j.molmed.2009.01.003.
51. Wang, J.Z., Liu, F., Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog. Neurobiol. 85:2 (2008), 148–175, 10.1016/j.pneurobio.2008.03.002.
52. Iqbal, K., Liu, F., Gong, C.X., Alonso Adel, C., Grundke-Iqbal, I., Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 118:1 (2009), 53–69, 10.1007/s00401-009-0486-3.
53. Gong, C.X., Lidsky, T., Wegiel, J., Zuck, L., Grundke-Iqbal, I., Iqbal, K., Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J. Biol. Chem. 275:8 (2000), 5535–5544.
54. Vosler, P.S., Brennan, C.S., Chen, J., Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol. Neurobiol. 38:1 (2008), 78–100, 10.1007/s12035-008-8036-x.
55. Aggeli, I.K., Beis, I., Gaitanaki, C., Oxidative stress and calpain inhibition induce alpha B-crystallin phosphorylation via p38-MAPK and calcium signalling pathways in H9c2 cells. Cell. Signal. 20:7 (2008), 1292–1302, 10.1016/j.cellsig.2008.02.019.
56. Chang, K.H., de Pablo, Y., Lee, H.P., Lee, H.G., Smith, M.A., Shah, K., Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer's disease. J. Neurochem. 113:5 (2010), 1221–1229, 10.1111/j.1471-4159.2010.06687.x.
57. Lee, D.G., Park, J., Lee, H.S., Lee, S.R., Lee, D.S., Iron overload-induced calcium signals modulate mitochondrial fragmentation in HT-22 hippocampal neuron cells. Toxicology 365 (2016), 17–24, 10.1016/j.tox.2016.07.022.
58. Spires, T.L., Orne, J.D., SantaCruz, K., Pitstick, R., Carlson, G.A., Ashe, K.H., Hyman, B.T., Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am. J. Pathol. 168:5 (2006), 1598–1607, 10.2353/ajpath.2006.050840.
59. Allen, B., Ingram, E., Takao, M., Smith, M.J., Jakes, R., Virdee, K., Yoshida, H., Holzer, M., Craxton, M., Emson, P.C., Atzori, C., Migheli, A., Crowther, R.A., Ghetti, B., Spillantini, M.G., Goedert, M., Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J. Neurosci. 22:21 (2002), 9340–9351.
60. Hambright, W.S., Fonseca, R.S., Chen, L., Na, R., Ran, Q., Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. 12 (2017), 8–17, 10.1016/j.redox.2017.01.021.
61. Ito, K., Eguchi, Y., Imagawa, Y., Akai, S., Mochizuki, H., Tsujimoto, Y., MPP+ induces necrostatin-1- and ferrostatin-1-sensitive necrotic death of neuronal SH-SY5Y cells. Cell Death Discov., 3, 2017, 17013, 10.1038/cddiscovery.2017.13.
62. Cahill, C.M., Lahiri, D.K., Huang, X., Rogers, J.T., Amyloid precursor protein and alpha synuclein translation, implications for iron and inflammation in neurodegenerative diseases. Biochim. Biophys. Acta 1790:7 (2009), 615–628, 10.1016/j.bbagen.2008.12.001.
63. Mandel, S., Amit, T., Bar-Am, O., Youdim, M.B., Iron dysregulation in Alzheimer's disease: multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog. Neurobiol. 82:6 (2007), 348–360, 10.1016/j.pneurobio.2007.06.001.
64. Ma, S., Henson, E.S., Chen, Y., Gibson, S.B., Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis., 7, 2016, e2307, 10.1038/cddis.2016.208.
65. Speer, R.E., Karuppagounder, S.S., Basso, M., Sleiman, S.F., Kumar, A., Brand, D., Smirnova, N., Gazaryan, I., Khim, S.J., Ratan, R.R., Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by “antioxidant” metal chelators: from ferroptosis to stroke. Free Radic. Biol. Med. 62 (2013), 26–36, 10.1016/j.freeradbiomed.2013.01.026.
66. Basuli, D., Tesfay, L., Deng, Z., Paul, B., Yamamoto, Y., Ning, G., Xian, W., McKeon, F., Lynch, M., Crum, C.P., Hegde, P., Brewer, M., Wang, X., Miller, L.D., Dyment, N., Torti, F.M., Torti, S.V., Iron addiction: a novel therapeutic target in ovarian cancer. Oncogene 36:29 (2017), 4089–4099, 10.1038/onc.2017.11.
67. Gaschler, M.M., Stockwell, B.R., Lipid peroxidation in cell death. Biochem. Biophys. Res. Commun. 482:3 (2017), 419–425, 10.1016/j.bbrc.2016.10.086.
68. Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A.J., Yang, W.S., Fridman, D.J., Wolpaw, A.J., Smukste, I., Peltier, J.M., Boniface, J.J., Smith, R., Lessnick, S.L., Sahasrabudhe, S., Stockwell, B.R., RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447:7146 (2007), 864–868, 10.1038/nature05859.
69. Yu, Y., Xie, Y., Cao, L., Yang, L., Yang, M., Lotze, M.T., Zeh, H.J., Kang, R., Tang, D., The ferroptosis inducer erastin enhances sensitivity of acute myeloid leukemia cells to chemotherapeutic agents. Mol. Cell. Oncol., 2(4), 2015, e1054549, 10.1080/23723556.2015.1054549.
70. Poursaitidis, I., Wang, X., Crighton, T., Labuschagne, C., Mason, D., Cramer, S.L., Triplett, K., Roy, R., Pardo, O.E., Seckl, M.J., Rowlinson, S.W., Stone, E., Lamb, R.F., Oncogene-selective sensitivity to synchronous cell death following modulation of the amino acid nutrient cystine. Cell Rep. 18:11 (2017), 2547–2556, 10.1016/j.celrep.2017.02.054.